SCHEMBL12379831

SCHEMBL12379831

CCCCCCCCCCCCn1c2ccc(-c3ccc(C)cc3)cc2c2cc3c(cc21)c1cc(-c2ccc(C)cc2)ccc1n3CCCCCCCCCCCC

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ICMT O60725 5/20 0.54
PSEN1 P49768 6/20 0.50
PSEN2 P49810 6/20 0.50
APH1B Q8WW43 6/20 0.50
NCSTN Q92542 6/20 0.50
APH1A Q96BI3 6/20 0.50
PSENEN Q9NZ42 6/20 0.50
SIRT2 Q8IXJ6 7/20 0.49
SIRT1 Q96EB6 4/20 0.49
PGR P06401 1/20 0.47
RORA P35398 1/20 0.47
RORC P51449 1/20 0.47
RORB Q92753 1/20 0.47
TLR8 Q9NR97 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12379846 0.97 ICMT (0.52) ICMTPSEN1PSEN2APH1BNCSTN
SCHEMBL13154161 0.92 PSEN1 (0.52) ICMTPSEN1PSEN2APH1BNCSTN
SCHEMBL12379849 0.91 PSEN1 (0.50) ICMTPSEN1PSEN2APH1BNCSTN
SCHEMBL14029768 0.91 PGR (0.56) ICMTPSEN1PSEN2APH1BNCSTN
SCHEMBL12379845 0.89 PSEN1 (0.48) ICMTPSEN1PSEN2APH1BNCSTN
SCHEMBL13125230 0.88 RORA (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL12379838 0.87 PSEN1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL12379842 0.87 PSEN1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14107127 0.85 PSEN1 (0.59) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14261684 0.85 PGR (0.48) ICMTPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9184391-B2 Compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2015-11-10 US disclosed
US-20140148567-A1 COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2014-05-29 US disclosed
US-8673959-B2 Polymer having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2014-03-18 US disclosed
US-8003807-B2 organic thin film transistor with a semiconductor layer including the small molecule having didodecylindolo[3,2-b]carbazole groups XEROX CORPORATION (US) 2011-08-23 US disclosed
US-7868186-B2 Device containing polymer having indolocarbazole- repeat unit and divalent linkage XEROX CORPORATION (US) 2011-01-11 US disclosed
US-7829727-B2 Device containing compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2010-11-09 US disclosed
US-20100230670-A1 DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2010-09-16 US disclosed
US-20090114909-A1 organic thin film transistor with a semiconductor layer including the polymer of 2,8-Bis(2-thienyl)-5,11-didodecylindolo[3,2-b]carbazole; organic photovoltaics XEROX CORPORATION (US) 2009-05-07 US disclosed
US-7528261-B2 Small molecule compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2009-05-05 US disclosed
US-20080207917-A1 POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2008-08-28 US disclosed
US-7396852-B2 Compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2008-07-08 US disclosed
US-20080103314-A1 SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2008-05-01 US disclosed
US-20070112167-A1 Device containing compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION 2007-05-17 US disclosed
US-20070112172-A1 Compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112172-A1 Compound having indolocarbazole moiety and divalent linkage INMT, IDO2, GRIN2C ICMT 112/4885PSEN1 3411/4885PSEN2 1708/4885
US-20080103314-A1 SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE SLC43A1, SLC7A5, KCNN2 ICMT 616/4885PSEN1 2508/4885PSEN2 1076/4885
US-20100230670-A1 DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE BRD4, BICRA, INMT ICMT 16/4885PSEN1 3828/4885PSEN2 2371/4885
US-20080207917-A1 POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE SGTA, MTCL3, SMC3 ICMT 202/4885PSEN1 4346/4885PSEN2 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.